Research

Hormonal

Myostatin and activin A inhibitors (e.g., bimagrumab, trevogrumab, garetosmab) combined with GLP-1 agonists can increase lean mass and reduce fat mass more effectively than GLP-1 agonists alone.

New drugs targeting myostatin (like bimagrumab) are being tested alongside GLP-1s to build muscle while losing fat. These are currently in clinical trials and not yet widely available.

ModerateSupportsMEDIUM confidence
Preliminary findings suggest a possible muscle gain of 6%-8% through the co-blockade of activin and myostatin.
Maja Cigrovski Berković et al. · World Journal of Diabetes · 2025

Why this rating

Based on phase 2 trials and preliminary findings; not yet large-scale phase 3 results.

Source

Saving muscle while losing weight: A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs

Maja Cigrovski Berković et al. · World Journal of Diabetes · 2025

DOI 10.4239/wjd.v16.i9.109123

narrative_reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →